Table 1.
Patients characteristics at the time of inclusion in the PRIAS study.
| Group A | Group B | Group C | |
|---|---|---|---|
| Total number of patients | 500 | 351 | 435 |
| Age at diagnosis median (IQR) years | 65 (60–70) | 65 (60–70) | 65 (60–70) |
| PSA at diagnosis median (IQR) ng/ml | 5.3 (3.9–6.7) | 6.0 (4.8–7.8) | 5.8 (4.6–7.8) |
| Prostate volume at diagnosis median (IQR) ml | 43 (35–57) | 43 (35–57) | 50 (38–63) |
| PSA Density at diagnosis median (IQR) ng/ml/ml | 0.12 (0.0–16) | 0.14 (0.10–0.18) | 0.12 (0.09–0.16) |
| T-stage | |||
| T1c | 413 (82.6%) | 315 (89.7%) | 385 (88.5%) |
| T2a | 80 (16.0%) | 32 (9.1%) | 43 (9.8%) |
| T2b | 3 (0.6%) | 4 (1.1%) | 6 (1.4%) |
| T2c | 4 (0.8%) | 0 (0%) | 1 (0.2%) |
| Number of systematic biopsy cores taken median (IQR) | 9 (7–12) | 12 (10–12) | 12 (11–14) |
| Outcome Systematic biopsies | |||
| No prostate cancer | 0 (0%) | 0 (0%) | 67 (15.4%) |
| GG 1 | 500 (100%) | 351 (100%) | 368 (84.6%) |
| Number of systematic biopsy cores positive for PCa | |||
| 0 | 0 (0%) | 0 (0%) | 67 (15.4%) |
| 1 | 357 (71.4%) | 176 (50.1%) | 202 (46.4%) |
| 2 | 138 (27.6) | 104 (29.6%) | 108 (24.8%) |
| 3 | 2 (0.4%) | 38 (10.8%) | 34 (7.8%) |
| 4 | 1 (0.2%) | 20 (5.7%) | 14 (3.2%) |
| >4 | 0 (0%) | 12 (3.4%) | 10 (2.3%) |
| Unknown | 2 (0.4%) | 1 (0.3%) | |
| MRI outcome | |||
| No lesion | 100 (23%) | ||
| PIRADS 3 | 104 (23.9%) | ||
| PIRADS 4 | 186 (42.8%) | ||
| PIRADS 5 | 37 (8.5%) | ||
| Missing data | 8 (1.8%) | ||
IQR interquartile range, GG Grade Group, PCa prostate cancer.